Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

18F-FDG PET in patients with long-COVID syndrome. A and B: Transaxial sections of group averaged, spatially normalized 18F-FDG PET scans in patients with long-COVID syndrome (A) and control patients (B). C: The pattern expression score (PES; *adjusted for age and sex, for illustration purposes) of the previously established COVID-19-related spatial covariance pattern was not significantly different between patients with long-COVID syndrome and control patients. Boxplots (grey), as well as individual values

News | Coronavirus (COVID-19)

Molecular Imaging Suggests Long-COVID Symptoms may be Caused by Fatigue

November 1, 2021 — Long-term cognitive problems after a COVID-19 diagnosis may be a result of fatigue rather than ...

November 01, 2021

News | Molecular Imaging

NorthStar Medical Radioisotopes Expansion Event Unveils Advanced Radioisotope Production Equipment and Breaks Ground on First-in-Kind Therapeutic Radioisotope Production Facility

October 29, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

October 29, 2021

RefleXion is developing biology-guided radiotherapy* (BgRT), which incorporates positron-emission tomography (PET) data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT).

News | Radiation Oncology

RefleXion Announces Newly Formed Scientific Advisory Board

October 20, 2021 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy (BgRT) as a ...

October 20, 2021

Sponsored Content

Videos | Proton Therapy

HYPERSCAN: Pencil Beam Scanning Delivered at Hyper Speed

Introducing HYPERSCAN , Pencil Beam Scanning Delivery HYPERSCAN enables tumor volumes to be scanned in a matter of ...

October 06, 2014

Images of uptake in bone metastasis in patient 2. Anterior whole-body (left) and SPECT/CT (right) images show uptake of 131I-GMIB-anti-HER2-VHH1 at level of large lytic bone metastasis, with soft-tissue component at sternal bone both at 2.5 h and at 24 h after injection. Small differences in area of uptake are explained by differences in patient positioning (arms up at 2.5 h and arms down at 24 h, to maximize patient comfort). Cts = counts. Image created by M. Keyaerts, University Hospital of Brussels (UZ B

News | Women's Health

New Radionuclide Therapy Identified for HER2-positive Breast Cancer Patients

October 5, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients ...

October 05, 2021

An illustration based on simulations by Rice University engineers shows a gadolinium ion (blue) in water (red and white), with inner-sphere water -- the water most affected by the gadolinium -- highlighted. The researchers’ models of gadolinium in water show there’s room for improvement in compounds used as contrast agents in clinical magnetic resonance imaging.

News | Magnetic Resonance Imaging (MRI)

Modern Simulations Could Improve MRIs

September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to ...

September 20, 2021

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.

News | Radiation Oncology

IBA and SCK CEN Join Forces to Enable Production of Actinium-225

September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and ...

September 17, 2021

Bicameral legislation in U.S. House and Senate designed to address equity issues in patient access and affordability for innovative diagnostic radiopharmaceuticals

News | Radiopharmaceuticals and Tracers

Blue Earth Diagnostics Supports Timely Consideration and Passage of the FIND Act of 2021 by U.S. Congress

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

September 17, 2021

Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond

Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)

5 Strategies for Improving Your Nuclear Radiology Lab

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

September 16, 2021

Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Feature | PET Imaging | By Todd Sasser, Ph.D.

The Role of PET Imaging in Preclinical Oncology

The use of positron emission tomography (PET) imaging in preclinical oncology investigations has shown the ability to ...

September 14, 2021

Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and commercialization collaboration to evaluate the use of piflufolastat F 18, Lantheus’ prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent, to enable real-time therapeutic guidance of biology-guided radiotherapy (BgRT) in prostate cancer using the RefleXion X1 platform.

News | PET Imaging

Lantheus and RefleXion Announce Collaboration with Potential to Improve Future Prostate Cancer Treatment

September 13, 2021 — Lantheus Holdings, Inc. and RefleXion Medical, Inc., today announced a development and ...

September 13, 2021

Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

News | RSNA

RSNA 2021 Showcases Latest Imaging Technologies, Solutions

September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical ...

September 13, 2021

NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing radiopharmaceuticals, today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).

News | Radiopharmaceuticals and Tracers

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

September 10, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

September 10, 2021

News | PET Imaging

Researchers Identify Mechanism That Can Help Guide Development of New STING-activating Drugs Using Imaging

September 8, 2021 — A new study from scientists at the UCLA Jonsson Comprehensive Cancer Center found that emerging ...

September 08, 2021

Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).

News | PET Imaging

Eckert & Ziegler Extends Gallium-68 Generator Portfolio in the United States

September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master File ...

September 03, 2021